14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
LXRX vs SANA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SANA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–4 Matrix Metrics)
SANA Overall Winner
6-Pillar Tally: LXRX 2 – 3 SANA (1 Tie)
Matrix Metrics: LXRX 4 – 4 SANA
As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LXRX carries a Unified Composite Score of 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin), whereas SANA carries 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: LXRX is currently in a Breakdown options structure phase (RSI 54.2); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LXRX vs SANA. Trailing 12-month operating profitability (LXRX -147.4% vs SANA 0.0%) and valuation multiples (LXRX N/M vs SANA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $797.0M market capitalization and -147.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
SANA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $605.3M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LXRX vs SANA Key Questions & Quantitative Answers
As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LXRX carries a Unified Composite Score of 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin), whereas SANA carries 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: LXRX is currently in a Breakdown options structure phase (RSI 54.2); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SANA leads the Growth & Scale pillar: LXRX posts -20.7% YoY revenue growth and -63.4% YoY earnings growth on $39M TTM revenue (91.4% gross margin, -147.4% operating margin), compared with SANA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LXRX generates $39M in USD-normalized revenue versus N/A for SANA. In operating R&D and SG&A reinvestment, LXRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SANA.
LXRX screens cheaper on headline valuation multiples. LXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 20.9x EV/Revenue (unreported FCF margin), whereas SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LXRX (-43.9% ROE) versus SANA (-79.5% ROE) capital efficiency.
In options market volatility and institutional positioning, LXRX carries 78.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.63β · 60% Vol realized risk). By comparison, SANA carries 105.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.